Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges	$ (93,504)	$ (923,607)	$ (263,080)	$ (1,000,850)
Fair value, measurements, nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total income (expense) from assets			(284,409)
Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges			(4,448)
Total income (expense) from intangible assets			(169,576)
Fair value, measurements, nonrecurring | U.S. Branded Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total income (expense) from intangible assets			(72,814)
Fair value, measurements, nonrecurring | International Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total income (expense) from intangible assets			(16,243)
Fair value, measurements, nonrecurring | Astora
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges			(5,041)
Total income (expense) from intangible assets			(16,287)
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0		0
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Generic Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	0		0
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Branded Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | International Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Astora
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	0		0
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0		0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | U.S. Generic Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	0		0
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | U.S. Branded Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | International Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | Astora
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	0		0
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	51,939		51,939
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | U.S. Generic Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	649		649
Certain segment intangible assets	45,966		45,966
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | U.S. Branded Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	0		0
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | International Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	5,324		5,324
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | Astora
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	0		0
Certain segment intangible assets	$ 0		$ 0